

For immediate release Seinäjoki, Finland 23.01.2025

## Eevia Health receives sales orders for 1,2 MSEK (102 KEUR)

Eevia Health Plc ("Eevia" or "The Company") has received sales orders for 102 KEUR from a European nutraceutical brand owner.

The customer, a European brand owner headquartered in Sweden, develops and markets effective herbal dietary supplements and cosmetics in over 50,000 pharmacies, health food shops, and other retail outlets across 38 countries, including China and the USA.

Eevia received two new sales orders totaling approximately 102 KEUR for Feno-Myrtillus<sup>®</sup> 1, a bilberry extract. One order for 51 KEUR was received recently but not announced due to an oversight; it will be delivered this week. The second order was received today and will be delivered in early February.

The product volumes for both orders are in stock, aiding cash flow, and supporting key assumptions for the current financial plan of reducing inventory levels. These are repeat orders, with more expected, showing Eevia's consistent business development and competitiveness in lower concentrate SKUs, though it faces tougher competition in higher concentrates SKUs from Asia.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc Email: <u>stein.ulve@eeviahealth.com</u> or <u>investor@eeviahealth.com</u> Telephone: +358 400 22 5967

## INFORMATION ABOUT EEVIA HEALTH PLC

*Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.* 

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing biomaterials that may dramatically impact human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit <u>www.eeviahealth.com</u> or follow Eevia Health on LinkedIn@EeviaHealth.